Quantcast

Latest Carboplatin Stories

2009-09-08 08:40:00

TUSTIN, Calif., Sept. 8 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today reported completion of patient enrollment in its Phase II trial evaluating bavituximab in combination with carboplatin and paclitaxel in advanced breast cancer patients.

2009-08-17 19:01:00

INDIANAPOLIS, Aug. 17 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. District Court for the Eastern District of Michigan has granted a motion by Sun Pharmaceuticals for partial summary judgment.

2009-07-27 07:00:00

INDIANAPOLIS, July 27 /PRNewswire-FirstCall/ -- Eli Lilly and Company continues to lead the way in advancing lung cancer treatment.

2009-07-02 06:30:00

CALGARY, July 2 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced today that patient enrolment has been completed in the Phase II component of a Phase I/II U.K. trial of REOLYSIN combined with paclitaxel/carboplatin for patients with advanced cancers.

2009-06-10 07:00:00

- Career Development Award to Study Biology of Bavituximab and Chemotherapy in Lung Cancer Awarded to Dr.

2009-06-03 07:02:00

- 71% Objective Tumor Response in Combination with Docetaxel in Advanced Breast Cancer - - 65% Objective Tumor Response in Combination with Carboplatin/Paclitaxel in Advanced Lung Cancer - - 64% Objective Tumor Response in Combination with Carboplatin/Paclitaxel in Advanced Breast Cancer - - Data in All Three Studies Surpassed Pre-Established Criteria for Expansion of Patient Enrollment - - Positive Initial Data across Indications and Chemotherapy Regimens Suggests Bavituximab Could...

2009-06-02 08:15:36

Daqing Li and colleagues, at the University of Pennsylvania School of Medicine, Philadelphia, have identified in vitro and in mice a way to enhance the anticancer effects of the commonly used platinum-based drug cisplatin.

2009-05-31 07:30:00

ORLANDO, Fla., May 31 /PRNewswire-FirstCall/ -- Eli Lilly and Company announced today that Phase III trial data showed the addition of Lilly's GEMZAR(R) (gemcitabine HCl for injection) to the current standard of care provided a statistically significant increase in progression-free survival at three years for women with locally advanced cervical cancer.

2009-05-12 07:00:00

INDIANAPOLIS, May 12 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) will unveil data from more than 50 studies at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Fla.

2009-04-27 07:00:00

- Updated Data from Initial Cohort Shows Nine of 14 Evaluable Patients Receiving Bavituximab in Combination with Carboplatin + Paclitaxel Achieved an Objective Tumor Response - - Patient Dosing Underway in Expansion Stage of Trial with Target of Enrolling 46 Patients Overall - TUSTIN, Calif., April 27 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc.


Word of the Day
ecotone
  • A transitional zone between two communities containing the characteristic species of each.
The word 'ecotone' comes 'eco-' plus a Greek root meaning 'tension'.